Torriani Francesca J, Ribeiro Ruy M, Gilbert Tari L, Schrenk Uschi M, Clauson Marietta, Pacheco DeeDee M, Perelson Alan S
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California 92103, USA.
J Infect Dis. 2003 Nov 15;188(10):1498-507. doi: 10.1086/379255. Epub 2003 Nov 13.
We studied hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics in 10 coinfected subjects in a trial of pegylated interferon-alpha2a (PEG-IFN) alone or combined with ribavirin (RBV), compared with IFN plus RBV for the treatment of HCV. Five subjects, 4 of whom were treated with PEG-IFN, achieved a sustained virological response, although it was delayed by >/=1 week in 3 subjects. The median treatment efficacy in blocking virion production was 99.7% in the PEG-IFN group and 60% with standard IFN. In 2 patients with detectable HIV loads before starting HCV study drugs, we observed a 1-log decrease in HIV RNA load. The estimated HCV virion half-life was longer in the HIV-coinfected subjects, which suggests that coinfection may contribute to a slower clearance of HCV. Although the early viral kinetics of coinfected subjects treated with PEG-IFN or IFN differ from those of singly infected subjects, the treatment response seems unaffected.
在一项关于聚乙二醇化干扰素α2a（PEG-IFN）单独使用或与利巴韦林（RBV）联合使用治疗丙型肝炎病毒（HCV）的试验中，我们研究了10例合并感染丙型肝炎病毒和人类免疫缺陷病毒（HIV）的受试者的病毒动态，并与使用干扰素加利巴韦林治疗HCV的情况进行了比较。5名受试者实现了持续病毒学应答，其中4名接受了PEG-IFN治疗，不过有3名受试者的应答延迟了≥1周。PEG-IFN组在阻断病毒体产生方面的中位治疗效果为99.7%，而标准干扰素组为60%。在开始使用HCV研究药物前HIV载量可检测的2例患者中，我们观察到HIV RNA载量下降了1个对数级。合并感染HIV的受试者中HCV病毒体的估计半衰期更长，这表明合并感染可能导致HCV清除较慢。尽管接受PEG-IFN或干扰素治疗的合并感染受试者的早期病毒动力学与单一感染受试者不同，但治疗反应似乎未受影响。
